Presentation is loading. Please wait.

Presentation is loading. Please wait.

Lung Cancer Incidence and Survival in England: An Analysis by Socioeconomic Deprivation and Urbanization  Sharma P. Riaz, MSc, Marie Horton, MSc, Jagdip.

Published byMaija-Leena Hiltunen Modified over 6 years ago

Similar presentations

Presentation on theme: "Lung Cancer Incidence and Survival in England: An Analysis by Socioeconomic Deprivation and Urbanization  Sharma P. Riaz, MSc, Marie Horton, MSc, Jagdip."— Presentation transcript:

1 Lung Cancer Incidence and Survival in England: An Analysis by Socioeconomic Deprivation and Urbanization  Sharma P. Riaz, MSc, Marie Horton, MSc, Jagdip Kang, BSc, Vivian Mak, MSc, Margreet Lüchtenborg, PhD, Henrik Møller, DM  Journal of Thoracic Oncology  Volume 6, Issue 12, Pages (December 2011) DOI: /JTO.0b013e31822b02db Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1. Map of England highlighting affluent and deprived areas based on the income domain of the Indices of Deprivation. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822b02db) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2. Map of England highlighting urban and rural areas.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822b02db) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3. Age-standardized incidence rate (ASR) in lung cancer incidence among males and females, respectively, by joint socioeconomic deprivation and urbanization, England, 2003–2007. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822b02db) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Lung Cancer Incidence and Survival in England: An Analysis by Socioeconomic Deprivation and Urbanization  Sharma P. Riaz, MSc, Marie Horton, MSc, Jagdip."

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer  Sarah Burdett, MSc,

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer  Sarah Burdett, MSc,
Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,
Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer  Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,

Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer  Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Danny R. Youlden, BSc, Susanna M. Cramb, MPH, Peter D. Baade, PhD 

Danny R. Youlden, BSc, Susanna M. Cramb, MPH, Peter D. Baade, PhD 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Rebecca Muirhead, MBChB, MRCP, Stuart G

Rebecca Muirhead, MBChB, MRCP, Stuart G
Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors  Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.

Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors  Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,
OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Similar presentations

Ads by Google